Morgan Stanley raised the firm’s price target on Bristol Myers (BMY) to $37 from $36 and keeps an Underweight rating on the shares. The firm expects many of the policy overhangs that dominated the biopharma conversation this year to wane in 2026, bringing the focus back to fundamentals, the analyst tells investors in a 2026 outlook note for the group.
Claim 55% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on BMY:
- Bristol Myers upgraded to Buy at Guggenheim ahead of 2026
- Bristol Myers upgraded to Buy from Neutral at Guggenheim
- Cautious Hold Rating on Bristol-Myers Squibb Amid Competitive Pressures in Hematology
- Bristol Myers says FDA grants priority review to sBLA for Opdivo
- Bristol Myers raises quarterly dividend 1.6% to 63c per share